Karen H. Lu, MD, on Addresses Gap in Genetic Counseling for Women at Risk for Ovarian Cancer

Video

The MD Anderson Cancer Center expert spoke about the disconnect in women who are at risk for ovarian cancer to actually receive genetic counseling.

Although genetic counseling surfaced decades ago, there is still a disconnect in women who are at risk for ovarian cancer to actually receive it, according to Karen H. Lu, MD.

At the 2020 ASCO Virtual Scientific Program, Lu – from the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center – presented on findings from the MAGENTA trial, designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.

She spoke to CancerNetwork about the aim of the study and why online genetic testing may be an added value to negate this disconnect in woman at risk for ovarian cancer.

Transcription:
Ovarian cancer is 1 of the deadliest cancers in women. We know that in the general population the risk is about 1.5%, so quite low. But we also know that there is women in the population that have an extremely high risk for ovarian cancer, from 20% up to 40% lifetime risk. So, that’s a huge difference.

We know that over the last 2 decades that clinical genetic testing can actually very precisely identify who are those women at very high risk of developing ovarian cancer. When you identify those women, you also allow them to institute preventive measures so that they are no longer at that increased risk.

Despite the fact that clinical genetic testing has been available for decades, the uptake is quite low. So, there was a gap between this medical information that is so powerful and then women not really taking advantage of that.

This study was all about looking at different ways to deliver genetic testing and counseling and wanting to make sure that it was safe.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content